Sign up to save your podcasts
Or
Share ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer's disease.
View all episodes
By American Academy of Neurology
4.6
2121 ratings
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer's disease.
More shows like Neurology Today in 5
View all
Radiolab
43,837 Listeners
Neurology® Podcast
299 Listeners
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
26 Listeners
JNNP Podcast
10 Listeners
Practical Neurology Podcast
53 Listeners
Pod Save America
87,868 Listeners
Interesting Times with Ross Douthat
7,244 Listeners
Neurology Minute
134 Listeners
MDS Podcast
9 Listeners
The Lancet Neurology in conversation with
6 Listeners
The Ezra Klein Show
16,525 Listeners
Stroke Alert
38 Listeners
The Weekly Show with Jon Stewart
11,013 Listeners
Inner Cosmos with David Eagleman
589 Listeners
Continuum Audio
80 Listeners